Eledon Pharmaceuticals, Inc. (ELDN)

2.9800

-0.0500

(-1.65%)

At close: June 5 at 4:00:01 PM EDT

2.9500

-0.03

(-1.01%)

Pre-Market: 8:00:02 AM EDT

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Cash, cash equivalents and short-term investments of $124.9 million as of March 31, 2025 IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today repo

GlobeNewswire 22 days ago

ELDN
-1.65%
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has caught the attention of institutional investors who hold a sizeable 46% stake

Key Insights Institutions' substantial holdings in Eledon Pharmaceuticals implies that they have significant influence...

Simply Wall St. last month

ELDN
-1.65%
We're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 2 months ago

ELDN
-1.65%
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantation expecte

GlobeNewswire 2 months ago

ELDN
-1.65%
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s websi

GlobeNewswire 3 months ago

ELDN
-1.65%
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L) with potential to improve both safety and efficacy compared to standard of care immunosuppression regimens IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that tegoprubart, the company’s investigational anti-C

GlobeNewswire 3 months ago

ELDN
-1.65%
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT). To register in advance for the presentation webcast, sign up here. A webcast replay wi

GlobeNewswire 4 months ago

ELDN
-1.65%
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immuno

GlobeNewswire 4 months ago

ELDN
-1.65%
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions

Key Insights Eledon Pharmaceuticals' significant individual investors ownership suggests that the key decisions are...

Simply Wall St. 6 months ago

ELDN
-1.65%
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Announced oversubscribed $85 million underwritten offering, with proceeds expected to extend cas

GlobeNewswire 6 months ago

ELDN
-1.65%
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Guggenheim Securities Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 1:30 p.m. ET (10:30 a.m. PT). To register in advance for the presentation webcast, sign up here. A webcast replay will be accessible following the live session on th

GlobeNewswire 6 months ago

ELDN
-1.65%
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 per share and (ii) pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of $3.649 per pre-funded warrant. The pre-funded warrants will be immediately exercisable and will have an exercise price of $0.001 per share. The gross pr

GlobeNewswire 7 months ago

ELDN
-1.65%
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and is on trajectory for insulin independence - Islet engraftment in the first two subjects with tegoprubart estimated three to five times higher than engraftment in three comparable subjects receiving standard of care tacrolimus-based

GlobeNewswire 7 months ago

ELDN
-1.65%
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 8:35 a.m. ET. To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s website under Events. About El

GlobeNewswire 8 months ago

ELDN
-1.65%
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Enrollment Completed Four Months Ahead of ScheduleIRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has successfully completed enrollment for its Phase 2 BESTOW clinical trial, which is designed to assess the safety and efficacy of its investigational immunosuppression therapy tegoprubart for the prevention of organ rejection in patients undergoing kidney transplantation. The trial reached its target enrollment of 12

GlobeNewswire 8 months ago

ELDN
-1.65%
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported recent business highlights f

GlobeNewswire 9 months ago

ELDN
-1.65%
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

80 Participants (Two-thirds of Projected Recruitment) EnrolledIRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. “As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America,” said D

GlobeNewswire 10 months ago

ELDN
-1.65%
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, 2024, in Boston, MA. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threaten

GlobeNewswire 10 months ago

ELDN
-1.65%

Performance Overview

Return	ELDN	S&P 500 (^GSPC)
YTD	-27.67%	+0.98%
1-Year	+4.93%	+10.93%
3-Year	-8.87%	+44.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Breaking

Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has caught the attention of institutional investors who hold a sizeable 46% stake

We're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash Wisely

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Performance Overview